It has been 15 years since the birth of human induced pluripotent stem cell (iPSC)
technology in 2007, and the scope of its application has been expanding. In addition to the …

Cell-replacement therapies have long been an attractive prospect for treating Parkinson
disease. However, the outcomes of fetal tissue-derived cell transplants in individuals with …

The specific loss of midbrain dopamine neurons (mDANs) causes major motor dysfunction
in Parkinson's disease, which makes cell replacement a promising therapeutic approach …

Induced pluripotent stem cells (iPS cells) are a promising source for a cell-based therapy to
treat Parkinson's disease (PD), in which midbrain dopaminergic neurons progressively …

Alzheimer's disease (AD) represents arguably the most significant social, economic, and
medical crisis of our time. Characterized by progressive neurodegenerative pathology, AD is …

The introduction of induced pluripotent stem cells (iPSCs) has opened up the potential for
personalized cell therapies and ushered in new opportunities for regenerative medicine …

Parkinson disease (PD) is characterized by loss of the A9 nigral neurons that provide
dopaminergic innervation to the striatum. This discovery led to the successful instigation of …

The banking of human leukocyte antigen (HLA)-homozygous-induced pluripotent stem cells
(iPSCs) is considered a future clinical strategy for HLA-matched cell transplantation to …

Differentiated cells have long been considered fixed in their identity. However, about 20
years ago, the first direct conversion of glial cells into neurons in vitro opened the field of" …

Degeneration of dopamine (DA) neurons in the midbrain underlies the pathogenesis of
Parkinson's disease (PD). Supplement of DA via L-DOPA alleviates motor symptoms but …